These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18023095)

  • 1. Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic.
    Kaliora AC; Stathopoulou MG; Triantafillidis JK; Dedoussis GV; Andrikopoulos NK
    World J Gastroenterol; 2007 Dec; 13(45):6031-6. PubMed ID: 18023095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chios mastic treatment of patients with active Crohn's disease.
    Kaliora AC; Stathopoulou MG; Triantafillidis JK; Dedoussis GV; Andrikopoulos NK
    World J Gastroenterol; 2007 Feb; 13(5):748-53. PubMed ID: 17278198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chios mastic fractions in experimental colitis: implication of the nuclear factor κB pathway in cultured HT29 cells.
    Papalois A; Gioxari A; Kaliora AC; Lymperopoulou A; Agrogiannis G; Papada E; Andrikopoulos NK
    J Med Food; 2012 Nov; 15(11):974-83. PubMed ID: 22891614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pilot study on antiplaque effects of mastic chewing gum in the oral cavity.
    Takahashi K; Fukazawa M; Motohira H; Ochiai K; Nishikawa H; Miyata T
    J Periodontol; 2003 Apr; 74(4):501-5. PubMed ID: 12747455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is Chios mastic gum effective in the treatment of functional dyspepsia? A prospective randomised double-blind placebo controlled trial.
    Dabos KJ; Sfika E; Vlatta LJ; Frantzi D; Amygdalos GI; Giannikopoulos G
    J Ethnopharmacol; 2010 Feb; 127(2):205-9. PubMed ID: 19961914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
    Grip O; Janciauskiene S; Lindgren S
    Inflamm Bowel Dis; 2004 May; 10(3):193-200. PubMed ID: 15290911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoregulatory properties of IL-13 in patients with inflammatory bowel disease; comparison with IL-4 and IL-10.
    Kucharzik T; Lügering N; Weigelt H; Adolf M; Domschke W; Stoll R
    Clin Exp Immunol; 1996 Jun; 104(3):483-90. PubMed ID: 9099934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
    Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pistacia lentiscus resin regulates intestinal damage and inflammation in trinitrobenzene sulfonic acid-induced colitis.
    Gioxari A; Kaliora AC; Papalois A; Agrogiannis G; Triantafillidis JK; Andrikopoulos NK
    J Med Food; 2011 Nov; 14(11):1403-11. PubMed ID: 21612460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MIF promotes a differential Th1/Th2/Th17 inflammatory response in human primary cell cultures: Predominance of Th17 cytokine profile in PBMC from healthy subjects and increase of IL-6 and TNF-α in PBMC from active SLE patients.
    De la Cruz-Mosso U; García-Iglesias T; Bucala R; Estrada-García I; González-López L; Cerpa-Cruz S; Parra-Rojas I; Gámez-Nava JI; Pérez-Guerrero EE; Muñoz-Valle JF
    Cell Immunol; 2018 Feb; 324():42-49. PubMed ID: 29397904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease.
    Reimund JM; Dumont S; Muller CD; Kenney JS; Kedinger M; Baumann R; Poindron P; Duclos B
    Gut; 1997 Apr; 40(4):475-80. PubMed ID: 9176074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mastic alleviates allergic inflammation in asthmatic model mice by inhibiting recruitment of eosinophils.
    Qiao J; Li A; Jin X; Wang J
    Am J Respir Cell Mol Biol; 2011 Jul; 45(1):95-100. PubMed ID: 20855649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.
    Bauditz J; Wedel S; Lochs H
    Gut; 2002 Feb; 50(2):196-200. PubMed ID: 11788559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease.
    Loganes C; Pin A; Naviglio S; Girardelli M; Bianco AM; Martelossi S; Tommasini A; Piscianz E
    World J Gastroenterol; 2016 Nov; 22(41):9117-9126. PubMed ID: 27895399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease.
    Segain JP; Raingeard de la Blétière D; Bourreille A; Leray V; Gervois N; Rosales C; Ferrier L; Bonnet C; Blottière HM; Galmiche JP
    Gut; 2000 Sep; 47(3):397-403. PubMed ID: 10940278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protease inhibitor cystatin C down-regulates the release of IL-β and TNF-α in lipopolysaccharide activated monocytes.
    Gren ST; Janciauskiene S; Sandeep S; Jonigk D; Kvist PH; Gerwien JG; Håkansson K; Grip O
    J Leukoc Biol; 2016 Oct; 100(4):811-822. PubMed ID: 27190304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukocyte dysfunction and reduced CTLA-4 expression are associated with perianal Crohn's disease.
    Duarte-Silva M; Parra RS; Feitosa MR; Nardini V; Maruyama SR; da Rocha JJR; Feres O; de Barros Cardoso CR
    Clin Exp Immunol; 2024 Jun; 217(1):78-88. PubMed ID: 38517030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-associated human retinal pigment epithelium interleukin-8 and monocyte chemotactic protein-1: immunochemical and in-situ hybridization analyses.
    Elner VM; Burnstine MA; Strieter RM; Kunkel SL; Elner SG
    Exp Eye Res; 1997 Dec; 65(6):781-9. PubMed ID: 9441701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mastic (Pistacia lentiscus) gum and oral health: a state-of-the-art review of the literature.
    Alwadi MAM; Sidhu A; Khaled MB; Aboul-Enein BH
    J Nat Med; 2023 Jun; 77(3):430-445. PubMed ID: 37147480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traditional uses, phytochemistry and pharmacology of Chios mastic gum (Pistacia lentiscus var. Chia, Anacardiaceae): A review.
    Pachi VK; Mikropoulou EV; Gkiouvetidis P; Siafakas K; Argyropoulou A; Angelis A; Mitakou S; Halabalaki M
    J Ethnopharmacol; 2020 May; 254():112485. PubMed ID: 32092498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.